Related Experiment Video

Updated: Jul 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose control peri-myocardial infarction

G D Braatvedt1

  • 1Department of Medicine and Endocrinology, University of Auckland, Auckland, New Zealand. g.braatvedt@auckland.ac.nz

Internal Medicine Journal
|April 12, 2008
PubMed

Insights

This review found that glucose-lowering treatments for acute myocardial infarction patients do not clearly reduce mortality. More research is needed to determine if these interventions offer benefits beyond standard hospital care.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Clinical Trials

Background:

  • Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
  • Glycemic control is a critical aspect of managing AMI patients.
  • The role of intensive glucose lowering in AMI outcomes remains under investigation.

Purpose of the Study:

  • To review and synthesize data from clinical trials on glucose-lowering interventions in AMI patients.
  • To assess the impact of these interventions on patient mortality.
  • To determine if glucose lowering provides benefits beyond routine care.

Main Methods:

  • Systematic review of available clinical trials.
  • Analysis of mortality data in patients with acute myocardial infarction.
  • Comparison of outcomes between glucose-lowering interventions and standard care.

Main Results:

  • Existing clinical trial data on glucose lowering in AMI is inconclusive.
  • No definitive evidence supports additional mortality benefits from glucose-lowering interventions.
  • The effectiveness of these interventions compared to routine care is not clearly established.

Conclusions:

  • Current evidence does not support routine use of specific glucose-lowering strategies to reduce mortality in AMI.
  • Further high-quality clinical trials are necessary to clarify the role of glucose management in AMI.
  • Individualized glycemic targets may be warranted based on patient-specific factors.

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...